BioCentury | Oct 25, 2018
Distillery Therapeutics


INDICATION: Epilepsy Patient sample and mouse studies suggest agonizing FFAR1 could help treat temporal lobe epilepsy. In postmortem brain tissue samples from patients with temporal lobe epilepsy, neocortical levels of FFAR1 protein were higher than...
BioCentury | Apr 13, 2018
Company News

Tasly gets Chinese rights to Lilly's diabetes candidate

Eli Lilly and Co. (NYSE:LLY) granted the Jiangsu Tasly Diyi Pharmaceutical Co. Ltd. subsidiary of Tasly Pharmaceutical Co. Ltd. (Shanghai:600535) exclusive rights to develop and commercialize LY-2922470 in China, including Hong Kong, Macao and Taiwan....
BioCentury | Sep 14, 2017

Numerate’s Intelligence

With three new partnerships formed since June, Numerate Inc. is picking up steam and demonstrating that industry and academic groups alike are finding utility in its AI platform, which can build robust predictive models for...
BioCentury | May 11, 2017

Feeding the Young

Increasing funding for innovative young researchers is making its way up NIH ’s to-do list. But to win over a skeptical community, the agency will likely need to redraw some boundaries and dig a bit...
BioCentury | Feb 2, 2017
Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Diabetes In vitro , cell culture and mouse studies identified a pyrrolidine-based FFAR1 agonist that could help treat Type II diabetes. Chemical synthesis and testing in cell-based assays of pyrrolidine analogs identified a compound that...
BioCentury | Jan 11, 2016

Growing up Galapagos

With a new partner for filgotinib, Galapagos N.V. is poised to enter Phase III testing for the first time, after a five-year period of Phase II disappointments and scuttled deals. The new deal with Gilead...
BioCentury | Mar 23, 2015
Product Development

Galapagos' evolution inflection

Data next month for filgotinib will be the first near-term opportunity for Galapagos N.V. to show it can complete its shift from hybrid discovery/service company into a product-focused play. The Janus kinase-1 (JAK-1) inhibitor will...
BioCentury | Feb 5, 2015
Distillery Therapeutics

Therapeutics: Free fatty acid receptor 2 (FFAR2; GPR43); FFAR3 (GPR41)

...Endocrine/metabolic disease INDICATION: Diabetes Cell culture and mouse studies suggest FFAR2 and FFAR3 antagonists could help...
...cell-specific knockout of FFAR2 and FFAR3 increased insulin secretion and glucose tolerance compared with normal FFAR2/FFAR3...
...models of type 2 diabetes. TARGET/MARKER/PATHWAY: Free fatty acid receptor 2 (FFAR2; GPR43 ); FFAR3 (GPR41...
BioCentury | Dec 4, 2014
Cover Story

GPCRs' grand plans

In a move to expand tenfold the number of known 3D structures of the highly druggable class of GPCRs, Amgen Inc. , Ono Pharmaceutical Co. Ltd. and Sanofi have teamed up with three academic organizations to...
BioCentury | Oct 13, 2014

Streamlining Takeda's Profit Story

After spending a decade growing the company via acquisition, Takeda Pharmaceutical Co. Ltd. is now focused on getting its costs in line with its global pharma peers. But to grow EPS in line with Street...
Items per page:
1 - 10 of 44